References

References 1-50

1. American Association for Cancer Research. AACR Cancer Progress Report 2022. Accessed: July 5, 2023. Available from: https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2022/09/AACR_CPR_2022.pdf
2. Siegel RL, et al. (2023) CA Cancer J Clin, 73: 17.
3. Giaquinto AN, et al. (2022) CA Cancer J Clin, 72: 524.
4. American Association for Cancer Research. AACR Cancer Progress Report 2021. Accessed: June 30, 2023. Available from: https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2021/10/AACR_CPR_2021.pdf
5. Surveillance, Epidemiology, and End Results (SEER) Program. Accessed: July 5, 2023. Available from: https://seer.cancer.gov/
6. Howlader N, et al. (2023) Cancer Epidemiol Biomarkers Prev, 32: 744.
7. Miller KD, et al. (2022) CA Cancer J Clin, 0: 1.
8. Gallicchio L, et al. (2022) J Natl Cancer Inst, 114: 1476.
9. American Association for Cancer Research. AACR Report on the Impact of COVID-19 on Cancer Research and Patient Care. Accessed: June 30, 2022. Available from: https://www.aacr.org/professionals/research/aacr-covid-19-and-cancer-report-2022/
10. Berrian J, et al. (2023) Cancer Med, 12: 7381.
11. Zhao J, et al. (2023) JCO Oncol Pract: OP2200522.
12. Kaufman HW, et al. (2022) JCO Clin Cancer Inform, 6: e2200102.
13. American Association for Cancer Research. AACR Cancer Disparities Progress Report 2022. Accessed: June 30, 2023. Available from: https://cancerprogressreport.aacr.org/disparities/
14. American Cancer Society. Cancer Facts and Figures for African Americans 2019-2021. Accessed: July 28, 2023. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-facts-and-figures-for-african-americans/cancer-facts-and-figures-for-african-americans-2019-2021.pdf
15. Kratzer TB, et al. (2023) CA Cancer J Clin, 73: 120.
16. Miller KD, et al. (2021) CA Cancer J Clin, 71: 466.
17. Haque AT, et al. (2023) J Natl Cancer Inst.
18. Jackson SS, et al. (2021) J Natl Cancer Inst, 113: 1221.
19. Ehrhardt MJ, et al. (2023) JAMA Netw Open, 6: e2255395.
20. Islami F, et al. (2023) Cancer, 129: 2522.
21. Fowler ME, et al. (2023) J Geriatr Oncol, 14: 101505.
22. Zahnd WE, et al. (2021) Int J Environ Res Public Health, 18.
23. Alnajar A, et al. (2023) JAMA Netw Open, 6: e234261.
24. Hoskins KF, et al. (2023) JAMA Oncol, 9: 536.
25. Zhang L, et al. (2023) JAMA Oncol, 9: 122.
26. Vince RA, Jr., et al. (2023) JAMA Netw Open, 6: e2250416.
27. World Health Organization. Social determinants of health. Accessed: July 31, 2023. Available from: https://www.who.int/health-topics/social-determinants-of-health
28. American Cancer Society. Cancer Facts and Figures. Accessed: July 5, 2023. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf
29. Ostrom QT, et al. (2022) Neuro Oncol, 24: v1.
30. International Agency for Research on Cancer. Global Cancer Observatory. Accessed: July 31, 2023. Available from: https://gco.iarc.fr/today/home
31. U.S. Department of Health and Human Services. Administration for Community Living. 2020 Profile of Older Americans. Accessed: Jul 6, 2023. Available from: https://acl.gov/sites/default/files/Aging%20and%20Disability%20in%20America/2020ProfileOlderAmericans.Final_.pdf
32. Cornelius ME, et al. (2023) MMWR Morb Mortal Wkly Rep, 72: 475.
33. Siegel DA, et al. (2021) JAMA Oncol, 7: 302.
34. Pelosof L, et al. (2017) J Natl Cancer Inst, 109.
35. Siegel RL, et al. (2023) CA Cancer J Clin, 73: 233.
36. Giannakis M, et al. (2023) Science, 379: 1088.
37. Sinicrope FA (2022) N Engl J Med, 386: 1547.
38. Abboud Y, et al. (2023) Gastroenterology, 164: 978.
39. Francoeur AA, et al. (2022) Int J Gynecol Cancer.
40. Shahmoradi Z, et al. (2022) JAMA, 328: 2267.
41. Global Burden of Disease Cancer C, et al. (2022) JAMA Oncol, 8: 420.
42. Institute for Health Metrics and Evaluation. Socio-demographic Index (SDI). Accessed: July 5, 2023. Available from: https://www.healthdata.org/taxonomy/glossary/socio-demographic-index-sdi
43. United Nations. Human Development Index. Accessed: July 5, 2023. Available from: https://hdr.undp.org/data-center/human-development-index#/indicies/HDI
44. Petrova D, et al. (2022) PLoS Med, 19: e1004110.
45. United Nations. Ageing. Accessed: July 6, 2023. Available from: https://www.un.org/en/global-issues/ageing
46. Editorial (2014) Lancet, 383: 1946.
47. Ugai T, et al. (2022) Nat Rev Clin Oncol, 19: 656.
48. GBD 2019 Cancer Risk Factors Collaborators. (2022) Lancet, 400:563
49. Pramesh CS, et al. (2022) Nat Med, 28: 649.
50. Chen S, et al. (2023) JAMA Oncol, 9: 465.

References 51-100

51. Collaborators GBDCC (2022) Lancet Gastroenterol Hepatol, 7: 627.
52. Rumgay H, et al. (2022) J Hepatol, 77: 1598.
53. Stelzle D, et al. (2021) Lancet Glob Health, 9: e161.
54. Parsons SK, et al. (2023) J Clin Oncol, 41: 3260.
55. Kuehn BM (2021) JAMA, 326: 2251.
56. Nayak RK, et al. (2021) JAMA Intern Med, 181: 1522.
57. Galkina Cleary E, et al. (2023) JAMA Health Forum, 4: e230511.
58. Unger JM, et al. (2023) J Clin Oncol, 41: 2020.
59. United for Medical Research. NIH’s Role in Sustaining the U.S. Economy. Accessed: August 1, 2023. Available from: https://www.unitedformedicalresearch.org/wp-content/uploads/2023/03/UMR_NIHs-Role-in-Sustaining-the-U.S.-Economy-2023-Update.pdf
60. Shiels MS, et al. (2023) Cancer Discov, 13: 1084.
61. Bertagnolli MM, et al. (2023) Cancer Discov, 13: 1049.
62. Hanahan D (2022) Cancer Discov, 12: 31.
63. National Cancer Institute. Diagnosis and Staging. Accessed: July 5, 2023. Available from: https://www.cancer.gov/about-cancer/diagnosis-staging
64. National Institutes of Health. FY 2003 – FY 2022 Distribution of Budget Authority Percentages for Basic and Applied Research. Accessed: July 5, 2023. Available from: https://officeofbudget.od.nih.gov/pdfs/Basic%20and%20Applied%20FY%202003%20-%20FY%202022%20(V).pdf
65. Fernandez-Medarde A, et al. (2021) Genes (Basel), 12.
66. Huang L, et al. (2021) Signal Transduct Target Ther, 6: 386.
67. Arteaga CL, et al. (2014) Clin Cancer Res, 20: S1.
68. National Cancer Institute. The Genetics of Cancer – NCI. Accessed: July 5, 2023. Available from: https://www.cancer.gov/about-cancer/causes-prevention/genetics
69. Gordhandas S, et al. (2023) J Natl Cancer Inst, 115: 560.
70. Frankell AM, et al. (2023) Nature, 616: 525.
71. Al Bakir M, et al. (2023) Nature, 616: 534.
72. Jaiswal S, et al. (2019) Science, 366.
73. Sherman MA, et al. (2022) Nat Biotechnol, 40: 1634.
74. National Cancer Institute. Targeted Therapy Drug List by Cancer Type. Accessed: July 5, 2023. Available from: https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/approved-drug-list
75. Vali-Pour M, et al. (2022) Nat Commun, 13: 3724.
76. Gabriel AAG, et al. (2022) J Natl Cancer Inst, 114: 1159.
77. Srinivasan P, et al. (2021) Nat Genet, 53: 1577.
78. Bradley RK, et al. (2023) Nat Rev Cancer, 23: 135.
79. Stanley RF, et al. (2022) Nat Cancer, 3: 536.
80. Jbara A, et al. (2023) Nature, 617: 147.
81. Martinez-Ruiz C, et al. (2023) Nature, 616: 543.
82. Wild SA, et al. (2022) Elife, 11.
83. Goncalves E, et al. (2022) Cancer Cell, 40: 835.
84. Uversky V. Posttranslational Modification. 2013. p 425.
85. Wang H, et al. (2023) Cancer Gene Ther, 30: 529.
86. Lu Y, et al. (2020) Mol Cancer, 19: 79.
87. Nepali K, et al. (2021) J Biomed Sci, 28: 27.
88. Phillips RE, et al. (2020) Cancer Cell, 38: 647.
89. Apte RS, et al. (2019) Cell, 176: 1248.
90. Zhou H, et al. (2021) Cells, 10.
91. Padera TP, et al. (2016) Annu Rev Biomed Eng, 18: 125.
92. Spranger S, et al. (2018) Annual Review of Cancer Biology, 2: 213.
93. Kim SK, et al. (2022) Front Pharmacol, 13: 868695.
94. Binnewies M, et al. (2018) Nat Med, 24: 541.
95. Mittal V (2018) Annu Rev Pathol, 13: 395.
96. Dagogo-Jack I, et al. (2018) Nat Rev Clin Oncol, 15: 81.
97. Lei Y, et al. (2021) J Hematol Oncol, 14: 91.
98. Gavish A, et al. (2023) Nature, 618: 598.
99. Holly JM, et al. (2013) Cancer Metastasis Rev, 32: 673.
100. Castaneda M, et al. (2022) Semin Cancer Biol, 87: 17.

References 101-150

101. Brabletz T, et al. (2018) Nat Rev Cancer, 18: 128.
102. Fischer KR, et al. (2015) Nature, 527: 472.
103. Wang G, et al. (2021) NPJ Precis Oncol, 5: 56.
104. Jin MZ, et al. (2020) Signal Transduct Target Ther, 5: 166.
105. Anderson NM, et al. (2020) Curr Biol, 30: R921.
106. Bejarano L, et al. (2021) Cancer Discov, 11: 933.
107. Malone ER, et al. (2020) Genome Med, 12: 8.
108. Adashek JJ, et al. (2021) Trends Cancer, 7: 15.
109. O’Dwyer PJ, et al. (2023) Nat Med, 29: 1349.
110. National Cancer Institute. ComboMATCH will test new combinations of cancer drugs – NCI. Accessed: July 5, 2023. Available from: https://www.cancer.gov/news-events/press-releases/2023/combomatch-precision-medicine-cancer-initiative
111. Mani DR, et al. (2022) Nat Rev Cancer, 22: 298.
112. Rodriguez H, et al. The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment. Cell. Volume 184: Elsevier Inc.; 2021. p 1661.
113. Li L, et al. (2023) Nat Commun, 14: 1666.
114. Shi W, et al. (2023) Nat Commun, 14: 835.
115. Wang Y, et al. (2023) Nat Commun, 14: 505.
116. Herbst SA, et al. (2022) Nat Commun, 13: 6226.
117. Lei JT, et al. (2023) Cold Spring Harb Perspect Med.
118. Dong L, et al. (2022) Cancer Cell, 40: 70.
119. Wahida A, et al. (2023) Nat Rev Cancer, 23: 43.
120. Mateo J, et al. (2022) Nat Med, 28: 658.
121. Collaborators GBDCRF (2022) Lancet, 400: 563.
122. Jha P, et al. (2013) N Engl J Med, 368: 341.
123. The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General. Atlanta (GA)2014.
124. Alexandrov LB, et al. (2016) Science, 354: 618.
125. Park-Lee E, et al. (2022) MMWR Morb Mortal Wkly Rep, 71: 1429.
126. Gentzke AS, et al. (2022) MMWR Surveill Summ, 71: 1.
127. Hu T, et al. (2020) J Am Heart Assoc, 9: e014381.
128. Centers for Disease Control and Prevention. Burden of Cigarette Use in the U.S. Accessed: July 31, 2023. Available from: https://www.cdc.gov/tobacco/campaign/tips/resources/data/cigarette-smoking-in-united-states.html
129. Ahmed AA, et al. (2015) Circ Heart Fail, 8: 694.
130. Duncan MS, et al. (2019) JAMA, 322: 642.
131. Centers for Disease Control and Prevention. Benefits of Quitting. Accessed: July 31, 2023. Available from: https://www.cdc.gov/tobacco/quit_smoking/how_to_quit/benefits/index.htm
132. Centers for Disease Control and Prevention. Smoking and Cancer. Accessed: July 5, 2023.
133. Tindle HA, et al. (2018) J Natl Cancer Inst, 110: 1201.
134. Herbst RS, et al. (2022) Clin Cancer Res, 28: 4861.
135. Gupta S, et al. (2018) Indian J Med Res, 148: 56.
136. Patil S, et al. (2022) J Oral Biol Craniofac Res, 12: 439.
137. National Cancer Institute. Cigars: Health Effects and Trends. Accessed: July 5, 2023. Available from: https://cancercontrol.cancer.gov/brp/tcrb/monographs/monograph-09
138. Prochaska JJ, et al. (2022) Tob Control, 31: e88.
139. Goriounova NA, et al. (2012) Cold Spring Harb Perspect Med, 2: a012120.
140. Goniewicz ML, et al. (2018) JAMA Netw Open, 1: e185937.
141. Yu V, et al. (2016) Oral Oncol, 52: 58.
142. Muthumalage T, et al. (2019) Sci Rep, 9: 19035.
143. Tehrani MW, et al. (2021) Chem Res Toxicol, 34: 2216.
144. National Academy of Sciences. Public health consequences of e-cigarettes. Accessed: July 6, 2023. Available from: https://nap.nationalacademies.org/catalog/24952/public-health-consequences-of-e-cigarettes
145. Cooper M, et al. (2022) MMWR Morb Mortal Wkly Rep, 71: 1283.
146. Wang TW, et al. (2020) MMWR Morb Mortal Wkly Rep, 69: 1310.
147. Islami F, et al. (2018) CA Cancer J Clin, 68: 31.
148. Reeves GK, et al. (2007) BMJ, 335: 1134.
149. Pati S, et al. (2023) Cancers (Basel), 15.
150. Bhaskaran K, et al. (2014) Lancet, 384: 755.

References 151-200

151. Lei YY, et al. (2021) BMC Cancer, 21: 839.
152. Recalde M, et al. (2023) Nat Commun, 14: 3816.
153. Centers for Disease Control and Prevention. Adult Obesity Facts. Accessed: July 5, 2023. Available from: https://www.cdc.gov/obesity/data/adult.html
154. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey 2017–March 2020 Prepandemic Data Files Development of Files and Prevalence Estimates for Selected Health Outcomes. Accessed: July 6, 2023. Available from: https://stacks.cdc.gov/view/cdc/106273
155. Jensen BW, et al. (2023) J Natl Cancer Inst, 115: 43.
156. Piercy KL, et al. (2018) JAMA, 320: 2020.
157. Matthews CE, et al. (2020) J Clin Oncol, 38: 686.
158. Patel AV, et al. (2019) Med Sci Sports Exerc, 51: 2391.
159. Moore SC, et al. (2016) JAMA Intern Med, 176: 816.
160. World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project. Expert Report 2018. Lactation and the risk of cancer. Accessed: July 6, 2023. Available from: https://www.wcrf.org/diet-activity-and-cancer/
161. Clinton SK, et al. (2020) J Nutr, 150: 663.
162. Lauby-Secretan B, et al. (2016) N Engl J Med, 375: 794.
163. Sengupta R, et al. (2019) Clin Cancer Res, 25: 5431.
164. Li H, et al. (2022) Gastroenterology, 162: 1088.
165. Hua H, et al. (2023) Front Oncol, 13: 1132306.
166. Adams TD, et al. (2023) Obesity (Silver Spring), 31: 574.
167. Clapp B, et al. (2022) Br J Surg, 110: 24.
168. Aminian A, et al. (2022) JAMA, 327: 2423.
169. Doumouras AG, et al. (2023) JAMA Surg, 158: 634.
170. Abildso CG, et al. (2023) MMWR Morb Mortal Wkly Rep, 72: 85.
171. Minihan AK, et al. (2022) Med Sci Sports Exerc, 54: 417.
172. Piercy KL, et al. (2018) JAMA, 320: 2020.
173. Stamatakis E, et al. (2023) JAMA Oncol.
174. Watts EL, et al. (2022) JAMA Netw Open, 5: e2228510.
175. Sheinboim D, et al. (2022) Cancer Res, 82: 4164.
176. Withall J, et al. (2011) BMC Public Health, 11: 507.
177. Centers for Disease Control and Prevention. Physical Inactivity is More Common among Racial and Ethnic Minorities in Most States. Accessed: July 5, 2023. Available from: https://blogs.cdc.gov/healthequity/2020/04/01/physical-inactivity/
178. Ferguson T, et al. (2022) Lancet Digit Health, 4: e615.
179. Chang K, et al. (2023) EClinicalMedicine, 56: 101840.
180. Juul F, et al. (2022) Am J Clin Nutr, 115: 211.
181. Wang L, et al. (2022) BMJ, 378: e068921.
182. Hang D, et al. (2023) J Natl Cancer Inst, 115: 155.
183. World Cancer Research Fund International. Wholegrains, vegetables, fruit and cancer risk. Accessed: July 5, 2023. Available from: https://www.wcrf.org/risk-factors/wholegrains-vegetables-fruit-and-cancer-risk/
184. Centers for Disease Control and Prevention. Fast Food Consumption Among Adults in the United States, 2013–2016. Accessed: July 5, 2023. Available from: https://www.cdc.gov/nchs/products/databriefs/db322.htm
185. Norman-Burgdolf H, et al. (2021) Prev Med Rep, 24: 101642.
186. Hua SV, et al. (2023) JAMA Netw Open, 6: e2323200.
187. Bleich SN, et al. (2021) JAMA Netw Open, 4: e2113527.
188. Edmondson EK, et al. (2022) J Nutr Sci, 11: e67.
189. Centers for Disease Control and Prevention. National Diabetes Statistics Report. Accessed: July 5, 2023. Available from: https://www.cdc.gov/diabetes/data/statistics-report/index.html
190. Zhang AMY, et al. (2021) Diabetes Metab J, 45: 285.
191. Rumgay H, et al. (2021) Lancet Oncol, 22:1071.
192. Goding Sauer A, et al. (2021) Cancer Epidemiol, 71: 101893.
193. National Cancer Institute. Alcohol and Cancer Risk Fact Sheet. Accessed: July 5, 2023. Available from: https://www.cancer.gov/about-cancer/causes-prevention/risk/alcohol/alcohol-fact-sheet
194. White AJ, et al. (2017) Am J Epidemiol, 186: 541.
195. Bagnardi V, et al. (2015) Br J Cancer, 112: 580.
196. Cao Y, et al. (2015) BMJ, 351: h4238.
197. Choi YJ, et al. (2018) Cancer Res Treat, 50: 474.
198. Yoo JE, et al. (2021) JAMA Netw Open, 4: e2120382.
199. Phillips JA (2021) Workplace Health Saf, 69: 395.
200. Gapstur SM et al. (2022) Cancer Epidemiol Biomarkers Prev, 31: 5.

References 201-250

201. Yoo JE, et al. (2022) JAMA Netw Open, 5: e2228544.
202. Seidenberg AB, et al. (2022) Am J Prev Med, 62: 174.
203. Strome A, et al. (2021) JAMA Netw Open, 4: e2134550.
204. Centers for Disease Control and Prevention. Youth Risk Behavior Surveillance System (YRBSS). Accessed: July 5, 2023. Available from: https://www.cdc.gov/healthyyouth/data/yrbs/index.htm
205. Centers for Disease Control and Prevention. National Health Interview Survey. Accessed: July 5, 2023. Available from: https://www.cdc.gov/nchs/nhis/index.htm
206. Wu S, et al. (2016) Am J Epidemiol, 183: 824.
207. Wu S, et al. (2014) Cancer Epidemiol Biomarkers Prev, 23: 1080.
208. Solazzo AL, et al. (2020) J Adolesc Health, 67: 609.
209. Skin Cancer Foundation. Indoor Tanning Legislation: Here’s Where We Stand. Accessed: July 5, 2023. Available from: https://www.skincancer.org/blog/indoor-tanning-legislation-heres-stand/
210. Bowers JM, et al. (2020) American Journal of Public Health, 110: 823.
211. Holman DM, et al. (2019) J Community Health, 44: 1086.
212. de Martel C, et al. (2020) Lancet Glob Health, 8: e180.
213. Centers for Disease Control and Prevention. Basic information about HPV and cancer. Accessed: July 28, 2022. Available from: https://www.cdc.gov/cancer/hpv/basic_info/
214. National Cancer Institute. HPV and Cancer. Accessed: August 11, 2022. Available from: https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-and-cancer
215. Pingali C, et al. (2022) MMWR Morb Mortal Wkly Rep, 71: 1101.
216. Torjesen I (2021) BMJ, 375: n2689.
217. Healthy People 2030. Increase the proportion of adolescents who get recommended doses of the HPV vaccine — IID‑08. Accessed: July 5, 2023. Available from: https://health.gov/healthypeople/objectives-and-data/browse-objectives/vaccination/increase-proportion-adolescents-who-get-recommended-doses-hpv-vaccine-iid-08
218. Alkrekshi A, et al. (2021) Clin Lymphoma Myeloma Leuk, 21: e832.
219. Lai YR, et al. (2022) Cancers (Basel), 14.
220. Center for Disease Control and Prevention. 2020 Viral Hepatitis Surveillance Report. Accessed: July 5, 2023. Available from: https://www.cdc.gov/hepatitis/statistics/2020surveillance/index.htm
221. National Cancer Institute. HIV Infection and Cancer Risk – NCI. Accessed: July 31, 2023. Available from: https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hiv-fact-sheet
222. Yarchoan R, et al. (2018) New England Journal of Medicine, 378: 1029.
223. Shiels MS, et al. (2017) Curr Opin HIV AIDS, 12: 6.
224. Hernandez-Ramirez RU, et al. (2017) Lancet HIV, 4: e495.
225. Haas CB, et al. (2022) Lancet HIV, 9: e700.
226. Lee DJ, et al. (2023) Front Oncol, 13: 1130754.
227. Kunz KR, et al. (2023) Front Public Health, 11: 1126066.
228. Li J, et al. (2022) J Natl Cancer Inst, 114: 210.
229. Jasra S, et al. (2022) Nat Med, 28: 468.
230. Dahm MM, et al. (2015) Occup Environ Med, 72: 670.
231. Pinkerton L, et al. (2020) Occup Environ Med, 77: 84.
232. Daniels RD, et al. (2015) Occup Environ Med, 72: 699.
233. Daniels RD, et al. (2014) Occup Environ Med, 71: 388.
234. Kang D, et al. (2008) Am J Ind Med, 51: 329.
235. Centers for Disease Control and Prevention. Findings from a Study of Cancer Among U.S. Fire Fighters. Accessed: July 5, 2023. Available from: https://blogs.cdc.gov/niosh-science-blog/2017/05/10/ff-cancer-facts/
236. American Lung Association. State of the Air 2023. Accessed: July 5, 2023. Available from: https://www.lung.org/research/sota
237. National Toxicology Program. National Toxicology Program Cancer Hazard Assessment Report on Night Shift Work and Light at Night. Accessed: July 5, 2023. Available from: https://ntp.niehs.nih.gov/sites/default/files/ntp/results/pubs/cancer_assessment/lanfinal20210400_508.pdf
238. International Agency for Research on Cancer. Night Shift. Accessed: July 5, 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK568199/
239. Figueiro MG, et al. (2020) J Safety Res, 74: 169.
240. Figueiro MG, et al. (2010) Int J Endocrinol, 2010: 829351.
241. Faraut B, et al. (2019) Front Neurosci, 13: 1366.
242. Nichols HB, et al. (2019) Ann Intern Med, 170: 22.
243. Ambrosone CB, et al. (2020) Cancer Res, 80: 4871.
244. Jung AY, et al. (2022) J Natl Cancer Inst.
245. Vohra SN, et al. (2022) Cancer Epidemiol Biomarkers Prev, 31: 561.
246. Millikan RC, et al. (2008) Breast Cancer Res Treat, 109: 123.
247. Lord SJ, et al. (2008) Cancer Epidemiol Biomarkers Prev, 17: 1723.
248. Fortner RT, et al. (2019) Breast Cancer Res, 21: 40.
249. Anstey EH, et al. (2017) Am J Prev Med, 53: S40.
250. Palmer JR, et al. (2014) J Natl Cancer Inst, 106.

References 251-300

251. John EM, et al. (2018) Int J Cancer, 142: 2273.
252. Li DP, et al. (2014) Asian Pac J Cancer Prev, 15: 4829.
253. Babic A, et al. (2020) JAMA Oncol, 6: e200421.
254. Ma H, et al. (2017) Breast Cancer Res, 19: 6.
255. Su Q, et al. (2021) BMC Med, 19: 90.
256. Amitay EL, et al. (2015) JAMA Pediatr, 169: e151025.
257. Stordal B (2023) Cancer Med, 12: 4616.
258. Hoyt-Austin A, et al. (2020) Obstet Gynecol, 136: 1154.
259. Chiang KV, et al. (2021) MMWR Morb Mortal Wkly Rep, 70: 769.
260. Beauregard JL, et al. (2019) MMWR Morb Mortal Wkly Rep, 68: 745.
261. Chlebowski RT, et al. (2020) JAMA, 324: 369.
262. Chlebowski RT, et al. (2008) Arch Intern Med, 168: 370.
263. Chlebowski RT, et al. (2009) N Engl J Med, 360: 573.
264. Collaborative Group on Hormonal Factors in Breast C (2019) Lancet, 394: 1159.
265. Wang SM, et al. (2020) Breast Cancer Res, 22: 129.
266. Jackson SS, et al. (2022) Trends Cancer, 8: 273.
267. de Blok CJM, et al. (2019) BMJ, 365: l1652.
268. de Nie I, et al. (2020) J Clin Endocrinol Metab, 105: e3293.
269. Raths F, et al. (2023) Cell Genom, 3: 100272.
270. Jochelson et al. (2021) Radiology, 299:36.
271. The ASCO Post. FDA Approves Iopromide Injection for Contrast-Enhanced Mammography – The ASCO Post. Accessed: July 31, 2023. Available from: https://ascopost.com/news/june-2023/fda-approves-iopromide-injection-for-contrast-enhanced-mammography
272. Hussein H, et al. (2023) Radiology, 306: e221785.
273. Conant EF, et al. (2023) Radiology, 307: e221571.
274. Crosby D, et al. (2022) Science, 375: eaay9040.
275. Bonney A, et al. (2022) Cochrane Database Syst Rev, 8: CD013829.
276. Mohl JT, et al. (2023) JAMA Netw Open, 6: e2251384.
277. Zorzi M, et al. (2022) Gut, 71: 561.
278. Kisiel JB, et al. (2023) J Clin Oncol, 41: 6642.
279. Kamineni A, et al. (2022) Ann Intern Med, 175: 1582.
280. U.S. Preventive Services Task Force. Grade definitions. Accessed: June 30, 2022. Available from: https://www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/grade-definitions
281. Mangione CM, et al. (2023) JAMA, 329: 1290.
282. Osarogiagbon RU, et al. (2023) Am Soc Clin Oncol Educ Book, 43: e389958.
283. Osarogiagbon RU, et al. (2022) J Clin Oncol, 40: 2094.
284. United States Preventive Services Taskforce. Draft Recommendation: Breast Cancer: Screening. Accessed: July 5, 2023. Available from: https://www.uspreventiveservicestaskforce.org/uspstf/draft-recommendation/breast-cancer-screening-adults
285. Monticciolo DL, et al. (2018) J Am Coll Radiol. 15: 408.
286. Densebreast-info.org. Dense Breast Reporting and Screening Coverage: State Law Map. Accessed: July 31, 2023. Available from: https://densebreast-info.org/legislative-information/state-legislation-map/
287. U.S. Food and Drug Administration. FDA Updates Mammography Regulations to Require Reporting of Breast Density Information and Enhance Facility Oversight | FDA. Accessed: July 5, 2023. Available from: https://www.fda.gov/news-events/press-announcements/fda-updates-mammography-regulations-require-reporting-breast-density-information-and-enhance
288. Davidson KW, et al. (2021) JAMA, 325: 1965.
289. Owens DK, et al. (2019) JAMA, 322: 652.
290. Kurian AW, et al. (2023) JAMA, 330: 43.
291. Radiological Society of North America. 20-year Lung Cancer Survival Rates in the International Early Lung Cancer Action Program (IELCAP). Accessed: July 5, 2023. Available from: https://press.rsna.org/pressrelease/2022_resources/2380/abstract.pdf
292. Kalavacherla S, et al. (2023) JAMA Netw Open, 6: e237504.
293. Star J, et al. (2023) Cancer Epidemiol Biomarkers Prev, 32:879.
294. Centers for Medicare and Medicaid Services. Removal of a National Coverage Determination & Expansion of Coverage of Colorectal Cancer Screening. Accessed: July 30, 2023. Available from: https://www.cms.gov/files/document/mm13017-removal-national-coverage-determination-expansion-coverage-colorectal-cancer-screening.pdf
295. Bauer C, et al. (2022) JAMA Netw Open, 5: e2233429.
296. Spencer JC, et al. (2023) Cancer, 129: 1569.
297. Sundararaman SK, et al. (2023) Am J Respir Crit Care Med, A1091.
298. Kaiser Family Foundation. Key Data on Health and Health Care by Race and Ethnicity. Accessed: July 5, 2023. Available from: https://www.kff.org/racial-equity-and-health-policy/report/key-data-on-health-and-health-care-by-race-and-ethnicity/
299. Roznovjak D, et al. (2023) JCO Oncol Pract, 19: e794.
300. Wiese D, et al. (2023) J Natl Cancer Inst, 115: 337.

References 301-350

301. Poulson MR, et al. (2022) J Thorac Cardiovasc Surg, 163: 1920.
302. Nelson NG, et al. (2023) Cancers (Basel), 15.
303. The Community Guide. TFFRS: Patient Navigation Services to Increase Cancer Screenings | The Community Guide. Accessed: July 5, 2023. Available from: https://www.thecommunityguide.org/pages/tffrs-cancer-screening-patient-navigation-services-to-increase-breast-cervical-colorectal-cancer-screenings.html
304. Community Preventive Services Task Force. 2022 Annual Report to Congress. Accessed: July 5, 2023. Available from: https://www.thecommunityguide.org/media/2023/pdf/2022-annual-report-congress-508.pdf
305. Champion VL, et al. (2023) JAMA Netw Open, 6: e2311004.
306. Pretsch PK, et al. (2023) Lancet Public Health, 8: e411.
307. Lau J, et al. (2022) Prev Med, 164: 107343.
308. Sharma KP, et al. (2022) Prev Med Rep, 29: 101904.
309. National Cancer Institute. National Cancer Plan. Accessed: July 5, 2023. Available from: https://nationalcancerplan.cancer.gov/national-cancer-plan.pdf
310. Xu H, et al. (2023) Clin Gastroenterol Hepatol, 21: 337.
311. Mikhael PG, et al. (2023) J Clin Oncol, 41: 2191.
312. Levy I, et al. (2022) Am J Gastroenterol, 117: 1871.
313. Shaukat A, et al. (2022) Gastroenterology, 163: 732.
314. National Cancer Institute. Artificial Intelligence. Accessed: June 30, 2022. Available from: https://www.cancer.gov/research/areas/diagnosis/artificial-intelligence
315. U.S. Food and Drug Administration. Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices. Accessed: July 5, 2023. Available from: https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices
316. Iqbal MJ, et al. (2021) Cancer Cell Int, 21: 270.
317. Connal S, et al. (2023) J Transl Med, 21: 118.
318. Christodoulou E, et al. (2023) NPJ Precis Oncol, 7: 21.
319. Doubeni CA, et al. (2023) Am Fam Physician, 107: 224.
320. Doubeni CA, et al. (2022) Cancer, 128 Suppl 4: 883.
321. Oxford Cancer. SYMPLIFY. Accessed: July 5, 2023. Available from: https://www.cancer.ox.ac.uk/research/projects/symplify
322. Sasieni P, et al. (2023) Br J Cancer, 129: 72.
323. National Cancer Institute. Liquid Biopsy Consortium. Accessed: July 5, 2023. Available from: https://prevention.cancer.gov/major-programs/liquid-biopsy-consortium
324. National Cancer Institute. Cancer Screening Research Network/MultiCancer Early Detection Evaluation. Accessed: July 5, 2023. Available from: https://deainfo.nci.nih.gov/advisory/joint/0622/Castle.pdf
325. Cronin KA, et al. (2022) Cancer, 128: 4251.
326. Arfe A, et al. (2023) J Natl Cancer Inst, 115:917
327. Shadbolt C, et al. (2023) JAMA Netw Open, 6: e2250996.
328. Kingwell K (2022) Nat Rev Drug Discov, 21: 702.
329. Li A, et al. (2020) Cancer, 126: 4838.
330. Quantum Leap Healthcare Collaborative. The I-SPY Trials. Accessed: July 31, 2023. Available from: https://www.ispytrials.org/
331. Wang H, et al. (2019) Curr Breast Cancer Rep, 11: 303.
332. IQVIA. Global Oncology Trends 2023. Accessed: July 5, 2023. Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports/global-oncology-trends-2023
333. Subbiah V (2023) Nat Med, 29: 49.
334. In: Bibbins-Domingo K, Helman A, editors. Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups. Washington (DC)2022.
335. Varma T, et al. (2023) BMJ Medicine, 2: e000395.
336. Green AK, et al. (2022) JAMA Oncol, 8: 1786.
337. Saez-Ibanez AR, et al. (2022) Nat Rev Drug Discov, 21: 870.
338. Mulligan KM, et al. (2023) Arch Dermatol Res, 315: 1033.
339. U.S. Food and Drug Administration. Drug Trials Snapshots Summary Report 2022. Accessed: July 31, 2023. Available from: https://www.fda.gov/media/168662/download
340. Kahn JM, et al. (2022) Cancer, 128: 216.
341. U.S. Food and Drug Administration. Diversity Plans to Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials; Draft Guidance for Industry; Availability. Accessed: July 5, 2023. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diversity-plans-improve-enrollment-participants-underrepresented-racial-and-ethnic-populations
342. National Institutes of Health. NIH awards $23 million to establish centers of excellence to study telehealth for cancer care. Accessed: July 5, 2023. Available from: https://www.nih.gov/news-events/news-releases/nih-awards-23-million-establish-centers-excellence-study-telehealth-cancer-care
343. Patel KB, et al. (2023) J Natl Compr Canc Netw, 21: 496.
344. Patel KB, et al. (2023) JAMA Netw Open, 6: e2250211.
345. Waseem N, et al. (2022) JAMA Netw Open, 5: e2220543.
346. Hamdy FC, et al. (2023) N Engl J Med, 388: 1547.
347. Lawrence W. History of Surgical Oncology. In: Norton JA, Barie PS, Bollinger RR, Chang AE, Lowry SF, Mulvihill SJ, et al., editors. Surgery. New York, NY: Springer New York; 2008. p 1889.
348. Gianfaldoni S, et al. (2017) Open Access Maced J Med Sci, 5: 521.
349. DeVita VT, Jr., et al. (2008) Cancer Res, 68: 8643.
350. Dobashi Y, et al. (2012) Chemotherapy, 1: 2.

References 351-400

351. Zhang Y, et al. (2020) Cell Mol Immunol, 17: 807.
352. Modi S, et al. (2022) N Engl J Med, 387: 9.
353. Gupta A, et al. (2023) Sci Rep, 13: 8190.
354. Kirtane K, et al. (2023) Cancer Med, 12.13687.
355. Liu X, et al. (2023) JAMA Netw Open, 6: e2251524.
356. Hougen HY, et al. (2023) JCO Oncol Pract: OP2300040.
357. Logan CD, et al. (2023) J Surg Res, 283: 1053.
358. Bikomeye JC, et al. (2023) J Natl Cancer Inst, 115: 652.
359. Burotto M, et al. (2019) Semin Oncol, 46: 83.
360. Gustafsson UO, et al. (2019) World J Surg, 43: 659.
361. Santa Mina D, et al. (2017) PM R, 9: S305.
362. Chakravarthy VB, et al. (2022) Cancer, 128: 4109.
363. Molenaar CJL, et al. (2023) JAMA Surg, 158: 572.
364. Altorki N, et al. (2023) N Engl J Med, 388: 489.
365. Topal H, et al. (2022) JAMA Netw Open, 5: e2248147.
366. Son SY, et al. (2022) JAMA Surg, 157: 879.
367. Di Benedetto F, et al. (2023) JAMA Surg, 158: 46.
368. Kuerer HM, et al. (2022) Lancet Oncol, 23: 1517.
369. Bartels SAL, et al. (2023) J Clin Oncol, 41: 2159.
370. Uramoto H, et al. (2014) Transl Lung Cancer Res, 3: 242.
371. Migliore M, et al. (2018) Ann Transl Med, 6: 90.
372. Huang C, et al. (2019) J Cancer, 10: 6888.
373. Sarkaria IS, et al. (2023) J Thorac Cardiovasc Surg.
374. Maroongroge S, et al. (2022) Int J Radiat Oncol Biol Phys, 112: 600.
375. Wang K, et al. (2021) CA Cancer J Clin, 71: 437.
376. Kunkler IH, et al. (2023) N Engl J Med, 388: 585.
377. Schrag D, et al. (2023) N Engl J Med, 389: 322.
378. Santoro M, et al. (2022) Applied Sciences, 12: 3223.
379. Ng J, et al. (2023) Front Oncol, 13: 1117874.
380. The ASCO Post Staff. FDA Approves Flotufolastat Fluorine-18 Injection, First Radiohybrid PSMA-Targeted PET Imaging Agent for Prostate Cancer. Accessed: July 5, 2023. Available from: https://ascopost.com/news/may-2023/fda-approves-flotufolastat-fluorine-18-injection-first-radiohybrid-psma-targeted-pet-imaging-agent-for-prostate-cancer/
381. East P, et al. (2022) Nat Commun, 13: 5632.
382. Rais R, et al. (2022) Sci Adv, 8: eabq5925.
383. Kotani D, et al. (2023) Nat Med, 29: 127.
384. Janne PA, et al. (2022) N Engl J Med, 387: 120.
385. Kotecha R, et al. (2022) N Engl J Med, 387: 1238.
386. Li BT, et al. (2022) N Engl J Med, 386: 241.
387. Riudavets M, et al. (2021) ESMO Open, 6: 100260.
388. National Cancer Institute. Enhertu Approved for Lung Cancer. Accessed: July 5, 2023. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2022/fda-lung-cancer-enhertu-her2?cid=eb_govdel
389. Sengupta R, et al. (2020) Clin Cancer Res, 26: 5055.
390. Goulart BHL, et al. (2021) Clin Lung Cancer, 22: e723.
391. Lemmon CA, et al. (2023) JCO Precis Oncol, 7: e2200294.
392. Osazuwa-Peters OL, et al. (2023) Clin Lung Cancer, 24: 305.
393. Sadik H, et al. (2022) JCO Precis Oncol, 6: e2200246.
394. Duke ES, et al. (2023) Clin Cancer Res: OF1.
395. Subbiah V, et al. (2022) Lancet Oncol, 23: 1261.
396. Dilawari A, et al. (2023) Clin Cancer Res, OF1.
397. Matulonis UA, et al. (2023) J Clin Oncol, 41: 2436.
398. Angelergues A, et al. (2023) Journal of Clinical Oncology, 41: LBA5507.
399. Bidard FC, et al. (2022) J Clin Oncol, 40: 3246.
400. Goyal L, et al. (2023) N Engl J Med, 388: 228.

References 401-450

401. Sengupta R, et al. (2021) Clin Cancer Res, 27: 5757.
402. Dankner M, et al. (2018) Oncogene, 37: 3183.
403. Flaherty KT, et al. (2012) N Engl J Med, 367: 1694.
404. Hargrave DR, et al. (2022) J Clin Oncol, 40: 2009.
405. Ahcene Djaballah S, et al. (2022) Am Soc Clin Oncol Educ Book, 42: 1.
406. Strickler JH, et al. (2023) Lancet Oncol, 24: 496.
407. de Botton S, et al. (2023) Blood Adv, 7: 3117.
408. Yanada M, et al. (2005) Leukemia, 19: 1345.
409. Erba HP, et al. (2023) Lancet, 401: 1571.
410. Verstovsek S, et al. (2018) Ann Oncol, 29: 1880.
411. Alu A, et al. (2022) J Hematol Oncol, 15: 138.
412. Zhang J, et al. (2022) Biomark Res, 10: 17.
413. Sengupta R, et al. (2020) Cancer Epidemiol Biomarkers Prev, 29: 1843.
414. Brown JR, et al. (2023) N Engl J Med, 388: 319.
415. de Bono J, et al. (2020) N Engl J Med, 382: 2091.
416. Agarwal N, et al. (2023) Lancet, 402: 291.
417. Hiam-Galvez KJ, et al. (2021) Nat Rev Cancer, 21: 345.
418. Mishra AK, et al. (2022) Diseases, 10.
419. McCarthy EF (2006) Iowa Orthop J, 26: 154.
420. Kaufmann SHE (2019) Front Immunol, 10: 684.
421. Waldman AD, et al. (2020) Nat Rev Immunol, 20: 651.
422. Goebeler ME, et al. (2020) Nat Rev Clin Oncol, 17: 418.
423. Marin-Acevedo JA, et al. (2021) J Hematol Oncol, 14: 45.
424. Pardoll DM (2012) Nat Immunol, 13: 1129.
425. Kahlon N, et al. (2022) JAMA Netw Open, 5: e2245269.
426. Garon EB, et al. (2019) J Clin Oncol, 37: 2518.
427. Pala L, et al. (2022) JAMA Netw Open, 5: e2226252.
428. Zhuo Y, et al. Changing Epidemiology of Hepatocellular Carcinoma and Role of Surveillance. In: Hoshida Y, editor. Hepatocellular Carcinoma: Translational Precision Medicine Approaches. Cham (CH)2019. p 53.
429. Abou-Alfa GK, et al. (2022) NEJM Evidence, 1: EVIDoa2100070.
430. Johnson ML, et al. (2023) J Clin Oncol, 41: 1213.
431. Oh D-Y, et al. (2022) NEJM Evidence, 1: EVIDoa2200015.
432. Kelley RK, et al. (2023) Lancet, 401: 1853.
433. Rosenberg JE, et al. (2023) J Clin Oncol, 41: 4505.
434. Challita-Eid PM, et al. (2016) Cancer Res, 76: 3003.
435. Paulson KG, et al. (2018) J Am Acad Dermatol, 78: 457.
436. Topalian SL, et al. (2019) JAMA Oncol, 5: 1411.
437. Lamba N, et al. (2022) JAMA Netw Open, 5: e2225459.
438. Voruganti T, et al. (2023) JAMA Oncol, 9: 334.
439. LeBlanc ML, et al. (2023) J Clin Oncol, 41: LBA4.
440. Schmid P, et al. (2020) N Engl J Med, 382: 810.
441. Altorki NK, et al. (2021) Lancet Oncol, 22: 824.
442. Carthon BC, et al. (2010) Clin Cancer Res, 16: 2861.
443. Liakou CI, et al. (2008) Proc Natl Acad Sci U S A, 105: 14987.
444. Ludford K, et al. (2023) J Clin Oncol, 41: 2181.
445. Cercek A, et al. (2022) N Engl J Med, 386: 2363.
446. Patel S, et al. (2022) Annals of Oncology, 33: S1408.
447. Gross ND, et al. (2022) N Engl J Med, 387: 1557.
448. Rohaan MW, et al. (2019) Virchows Arch, 474: 449.
449. Mitra A, et al. (2023) Front Immunol, 14: 1188049.
450. Brentjens RJ, et al. (2011) Blood, 118: 4817.

References 451-500

451. Porter DL, et al. (2011) N Engl J Med, 365: 725.
452. Grupp SA, et al. (2013) N Engl J Med, 368: 1509.
453. Maude SL, et al. (2018) N Engl J Med, 378: 439.
454. Laetsch TW, et al. (2023) J Clin Oncol, 41: 1664.
455. Dana H, et al. (2021) Acta Pharm Sin B, 11: 1129.
456. Westin JR, et al. (2023) N Engl J Med.
457. Liu C, et al. (2021) Adv Sci (Weinh), 8: e2004433.
458. Conlon KC, et al. (2019) J Interferon Cytokine Res, 39: 6.
459. Golomb HM, et al. (1986) J Clin Oncol, 4: 900.
460. McDermott DF, et al. (2006) Semin Oncol, 33: 583.
461. Xue D, et al. (2021) Antib Ther, 4: 123.
462. Mond HG, et al. (1981) Pacing Clin Electrophysiol, 4: 304.
463. Bree KK, et al. (2021) Hematol Oncol Clin North Am, 35: 513.
464. Boorjian SA, et al. (2021) Lancet Oncol, 22: 107.
465. Lobo N, et al. (2021) Nat Rev Urol, 18: 611.
466. Lee A (2023) Drugs, 83: 353.
467. Melani C, et al. (2023) Lancet Haematol, 10: e346.
468. Baselga J, et al. (2015) Clin Cancer Res, 21: S1.
469. Tian Z, et al. (2021) J Hematol Oncol, 14: 75.
470. Moreau P, et al. (2022) N Engl J Med, 387: 495.
471. Leslie M (2023) Cancer Discov, 13: OF1.
472. Budde LE, et al. (2022) Lancet Oncol, 23: 1055.
473. Sethi A, et al. (2019) J Oral Maxillofac Pathol, 23: 284.
474. Dickinson MJ, et al. (2022) N Engl J Med, 387: 2220.
475. Zahavi D, et al. (2018) Antib Ther, 1: 7.
476. Desai AV, et al. (2022) J Clin Oncol, 40: 4107.
477. Grossman JE, et al. (2021) Oncogene, 40: 1393.
478. Aldrighetti CM, et al. (2021) JAMA Netw Open, 4: e2133205.
479. Nassar AH, et al. (2022) Cancer Cell, 40: 1161.
480. Jenkins RW, et al. (2018) Br J Cancer, 118: 9.
481. Gauci ML, et al. (2019) Clin Cancer Res, 25: 946.
482. Hegde PS, et al. (2020) Immunity, 52: 17.
483. Hodi FS, et al. (2016) J Clin Oncol, 34: 1510.
484. Claret L, et al. (2018) Clin Cancer Res, 24: 3292.
485. Messmer AS, et al. (2021) Wien Klin Wochenschr, 133: 1318.
486. Neelapu SS, et al. (2017) N Engl J Med, 377: 2531.
487. Gust J, et al. (2017) Cancer Discov, 7: 1404.
488. Maude SL, et al. (2014) Cancer J, 20: 119.
489. Sengupta R, et al. (2018) Clin Cancer Res, 24: 4351.
490. Shimabukuro-Vornhagen A, et al. (2018) J Immunother Cancer, 6: 56.
491. Cappell KM, et al. (2023) Nat Rev Clin Oncol, 20: 359.
492. Cappell KM, et al. (2020) J Clin Oncol, 38: 3805.
493. Brudno JN, et al. (2019) Blood Rev, 34: 45.
494. Brudno JN, et al. (2016) Blood, 127: 3321.
495. Locke FL, et al. (2019) Lancet Oncol, 20: 31.
496. Logue JM, et al. (2021) Haematologica, 106: 978.
497. Cordeiro A, et al. (2020) Biol Blood Marrow Transplant, 26: 26.
498. Aggarwal C, et al. (2016) Annals of Oncology, 27.
499. Postow MA, et al. (2018) N Engl J Med, 378: 158.
500. Wang PF, et al. (2017) Front Pharmacol, 8: 730.

References 501-550

501. Choi J, et al. (2020) Immune Netw, 20: e9.
502. Johnson DB, et al. (2022) Nat Rev Clin Oncol, 19: 254.
503. Mor A, et al. (2021) Front Cell Dev Biol, 9: 790386.
504. Cardena-Gutierrez A, et al. (2022) Front Med (Lausanne), 9: 908752.
505. Chaput N, et al. (2017) Ann Oncol, 28: 1368.
506. Manson G, et al. (2016) Ann Oncol, 27: 1199.
507. Martins F, et al. (2019) Nat Rev Clin Oncol, 16: 563.
508. Khalid AB, et al. (2022) J Natl Compr Canc Netw, 20: 1316.
509. Zhang XT, et al. (2022) Cancer Cell Int, 22: 363.
510. Li M, et al. (2023) J Natl Cancer Inst, 115: 295.
511. Muhimpundu S, et al. (2021) Cancers (Basel), 13.
512. Ahn JC, et al. (2022) Hepatology.
513. Alqazaqi R, et al. (2022) JAMA Netw Open, 5: e2228877.
514. Al Hadidi S, et al. (2022) JAMA Netw Open, 5: e228161.
515. Xie N, et al. (2023) Signal Transduct Target Ther, 8: 9.
516. Grimmett E, et al. (2022) Discov Oncol, 13: 31.
517. Saxena M, et al. (2021) Nat Rev Cancer, 21: 360.
518. Rojas LA, et al. (2023) Nature, 618: 144.
519. Mørk SK, et al. (2023) J Clin Oncol, 41: 9551.
520. Huff AL, et al. (2022) J Clin Invest, 132.
521. Lorentzen CL, et al. (2022) Lancet Oncol, 23: e450.
522. Karasarides M, et al. (2022) Cancer Immunol Res, 10: 372.
523. Alilou M, et al. (2022) Sci Adv, 8: eabq4609.
524. Pardoll DM (2012) Nature Reviews Cancer, 12.
525. Acharya N, et al. (2020) J Immunother Cancer, 8.
526. Tagliamento M, et al. (2021) Immunotargets Ther, 10: 185.
527. Chauvin JM, et al. (2020) J Immunother Cancer, 8.
528. Cho BC, et al. (2022) Lancet Oncol, 23: 781.
529. Johnson ML, et al. (2022) J Clin Oncol, 40: 397600.
530. Chiang EY, et al. (2022) J Immunother Cancer, 10.
531. Chao MP, et al. (2012) Curr Opin Immunol, 24: 225.
532. Chao MP, et al. (2019) Front Oncol, 9: 1380.
533. Jiang Z, et al. (2021) J Hematol Oncol, 14: 180.
534. Shafer P, et al. (2022) Front Immunol, 13: 835762.
535. Saez-Ibanez AR, et al. (2022) Nat Rev Drug Discov, 21: 631.
536. Liu S, et al. (2021) J Hematol Oncol, 14: 7.
537. Daher M, et al. (2021) Clin Transl Immunology, 10: e1274.
538. Trujillo JA, et al. (2018) Cancer Immunol Res, 6: 990.
539. Zhao Y, et al. (2022) Cancers (Basel), 14.
540. Rohaan MW, et al. (2022) N Engl J Med, 387: 2113.
541. Bashor CJ, et al. (2022) Nat Rev Drug Discov, 21: 655.
542. Tran E, et al. (2016) N Engl J Med, 375: 2255.
543. Martinov T, et al. (2023) Annu Rev Cancer Biol, 7: 331.
544. Chiesa R, et al. (2023) N Engl J Med. Epub ahead of print.
545. Vasan N, et al. (2019) Nature, 575: 299.
546. Jin H, et al. (2023) Nat Rev Drug Discov, 22: 213.
547. Obenauf AC (2022) Sci Transl Med, 14: eadd0887.
548. Upadhaya S, et al. (2022) Nat Rev Drug Discov, 21: 482.
549. Zhu S, et al. (2021) J Hematol Oncol, 14: 156.
550. Bilusic M, et al. (2021) J Natl Cancer Inst, 113: 799.

References 551-601

551. Higham CE, et al. (2020) Eur J Cancer, 132: 207.
552. Lu Y, et al. (2022) J Hematol Oncol, 15: 47.
553. Li B, et al. (2023) Cancers (Basel), 15.
554. Cortes J, et al. (2022) N Engl J Med, 387: 217.
555. ClinicalTrials.gov. Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC. Accessed: July 31, 2023. Available from: https://www.clinicaltrials.gov/study/NCT02343952
556. Murphy CC, et al. (2023) JAMA Oncol, 9: 1147.
557. Ellington TD, et al. (2023) PLoS One, 18: e0284051.
558. Patel VR, et al. (2023) JAMA Oncol, 9: 1001.
559. Ni J, et al. (2020) Cancer Manag Res, 12: 5597.
560. Law ML (2022) Front Pain Res (Lausanne), 3: 971295.
561. National Cancer Institute. Treating Cancer Cachexia: Progress Looks Possible. Accessed: July 5, 2023. Available from: https://www.cancer.gov/about-cancer/treatment/research/cachexia
562. Chiaravalloti A, et al. (2023) J Nucl Med, 64: 508.
563. Lange M, et al. (2023) J Natl Cancer Inst, 115: 322.
564. Scott LC, et al. (2021) MMWR Morb Mortal Wkly Rep, 70: 1.
565. Zhu C, et al. (2023) JACC CardioOncol, 5: 55.
566. Lozano AX, et al. (2022) Nat Med, 28: 353.
567. Bryan CJ, et al. (2023) JAMA Oncol, 9: 303.
568. Rincones O, et al. (2021) Cancer Manag Res, 13: 3803.
569. Papini C, et al. (2023) Cancer, 129: 1117.
570. Chang WH, et al. (2022) Nat Med, 28: 860.
571. Chan ASW, et al. (2022) Front Public Health, 10: 912980.
572. Potter AL, et al. (2023) JAMA Oncol, 9: 308.
573. Andersen BL, et al. (2022) Psychosom Med, 84: 215.
574. Andersen BL, et al. (2023) PLoS One, 18: e0282206.
575. Breitbart W, et al. (2014) Psychooncology, 23: 339.
576. McFarland DC, et al. (2022) Cancer, 128: 2504.
577. Galea I (2021) Cell Mol Immunol, 18: 2489.
578. Yabroff KR, et al. (2022) J Natl Cancer Inst, 114: 863.
579. Shih YT, et al. (2022) J Natl Cancer Inst, 114: 1392.
580. Grabowski DC, et al. (2023) JAMA Netw Open, 6: e2315823.
581. Ehsan AN, et al. (2023) JAMA Netw Open, 6: e2255388.
582. Graboyes EM, et al. (2022) J Natl Cancer Inst, 114: 1593.
583. Fan Q, et al. (2022) J Natl Cancer Inst, 114: 1584.
584. Raber M, et al. (2022) J Natl Cancer Inst, 114: 1577.
585. Ghazal LV, et al. (2023) JAMA Netw Open, 6: e235897.
586. Bradley CJ, et al. (2023) J Clin Oncol, 41: 2939.
587. Siegel RL, et al. (2021) CA Cancer J Clin, 71: 7.
588. Armstrong GT, et al. (2014) J Clin Oncol, 32: 1218.
589. Hudson MM, et al. (2013) JAMA, 309: 2371.
590. Meijer AJM, et al. (2022) Cancer, 128: 169.
591. Schulte F, et al. (2022) JAMA Netw Open, 5: e2227225.
592. Dixon SB, et al. (2023) Lancet, 401: 1447.
593. Williams AM, et al. (2023) J Natl Cancer Inst, 115: 200.
594. Plonski NM, et al. (2023) JAMA Netw Open, 6: e2310325.
595. Hsu TW, et al. (2023) J Clin Oncol, 41: 2054.
596. National Cancer Institute. Cancer Among Adolescents and Young Adults (AYAs). Accessed: Jul 5, 2023. Available from: https://seer.cancer.gov/statfacts/html/aya.html
597. Chao C, et al. (2020) J Clin Oncol, 38: 3161.
598. Xie J, et al. (2022) Cancer Med, 11: 3508.
599. Alliance for Fertility Preservation. State Laws & Legislation. Accessed: July 31, 2023. Available from: https://www.allianceforfertilitypreservation.org/state-legislation/
600. Stensheim H, et al. (2009) J Clin Oncol, 27: 45.

References 601-650

601. Jorgensen K, et al. (2022) Obstet Gynecol, 140: 939.
602. Betts AC, et al. (2023) J Natl Cancer Inst, 115: 619.
603. Anderson C, et al. (2017) JAMA Oncol, 3: 1078.
604. Partridge AH, et al. (2023) N Engl J Med, 388: 1645.
605. Ryder-Burbidge C, et al. (2021) Cancers (Basel), 13.
606. Berkman AM, et al. (2023) J Natl Cancer Inst, 115: 447.
607. Meernik C, et al. (2023) J Adolesc Young Adult Oncol.
608. Ji X, et al. (2023) J Clin Oncol, 41: 1909.
609. Mohile SG, et al. (2016) Cancer, 122: 2459.
610. Poisson J, et al. (2021) J Cachexia Sarcopenia Muscle, 12: 1477.
611. Dunne RF, et al. (2019) J Geriatr Oncol, 10: 415.
612. Cruz-Jentoft AJ, et al. (2019) Age Ageing, 48: 16.
613. Fukuda Y, et al. (2016) Gastric Cancer, 19: 986.
614. Wang SL, et al. (2016) Ann Surg Oncol, 23: 556.
615. Tegels JJ, et al. (2015) J Surg Oncol, 112: 403.
616. Rees-Punia E, et al. (2023) JAMA Oncol, 9: 79.
617. Campbell KL, et al. (2022) JCO Oncol Pract, 18: e697.
618. Brown JC, et al. (2023) Br J Sports Med, 57: 965.
619. Joaquim A, et al. (2022) Front Oncol, 12: 955505.
620. Mavropalias G, et al. (2023) Breast Cancer, 30: 139.
621. Chen LH, et al. (2022) JAMA Netw Open, 5: e2242660.
622. Morice P, et al. (2012) Lancet, 379: 558.
623. Deshmukh AA, et al. (2018) JNCI Cancer Spectr, 2: pky022.
624. Schwedhelm C, et al. (2016) Nutr Rev, 74: 737.
625. Castro-Espin C, et al. (2022) Nutrients, 14.
626. Liu ZY, et al. (2022) J Transl Med, 20: 376.
627. Wang X, et al. (2023) JAMA Netw Open, 6: e2311966.
628. Young AL, et al. (2023) JAMA Oncol, 9: 981.
629. Bakitas M, et al. (2009) JAMA, 302: 741.
630. Zimmermann C, et al. (2014) Lancet, 383: 1721.
631. Temel JS, et al. (2010) N Engl J Med, 363: 733.
632. Bigi S, et al. (2023) Front Public Health, 11: 1092145.
633. Luo XF, et al. (2023) Front Oncol, 13: 1104447.
634. Gregoire C, et al. (2022) Curr Opin Oncol, 34: 270.
635. Koizumi T, et al. (2023) Cancer, 129: 2568.
636. Akechi T, et al. (2023) J Clin Oncol, 41: 1069.
637. Fu X, et al. (2022) Front Public Health, 10: 927370.
638. Lang-Rollin I, et al. (2018) Dialogues Clin Neurosci, 20: 13.
639. Dos Santos M, et al. (2020) Cancer, 126: 5328.
640. Lleras de Frutos M, et al. (2020) Psychooncology, 29: 1995.
641. Menger F, et al. (2021) Support Care Cancer, 29: 7013.
642. Gorin SS, et al. (2017) Ann Behav Med, 51: 532.
643. Edward JS, et al. (2023) JCO Oncol Pract, 19: e696.
644. Oluwole SF, et al. (2003) J Am Coll Surg, 196: 180.
645. Percac-Lima S, et al. (2016) JAMA Intern Med, 176: 930.
646. Ritvo PG, et al. (2015) Cancer Epidemiol Biomarkers Prev, 24: 506.
647. Percac-Lima S, et al. (2015) Cancer, 121: 1662.
648. Liang H, et al. (2020) Health Care Manage Rev, 45: 364.
649. Basch E, et al. (2023) J Clin Oncol, 41: 3724.
650. Friends of Cancer Research. Broadening the Definition of Tolerability in Cancer Clinical Trials to Better Measure the Patient Experience. Accessed: July 31, 2023. Available from: https://friendsofcancerresearch.org/wp-content/uploads/Comparative-Tolerability-Whitepaper_FINAL.pdf

References 651-700

651. Natori A, et al. (2023) J Clin Oncol, 41: 285.
652. Thanarajasingam G, et al. (2022) Lancet Haematol, 9: e374.
653. Temple-Oberle C, et al. (2023) JAMA Surg, 158: 693.
654. Graetz I, et al. (2023) Cancer Med, 12: 6190.
655. Villanueva-Bueno C, et al. (2022) Front Public Health, 10: 978783.
656. National Partnership for Women and Families. Paid leave could keep more than 6 million caregivers connected to the labor force by 2030. Accessed: June 30, 2023. Available from: https://www.nationalpartnership.org/our-work/resources/economic-justice/paid-leave/paid-leave-caregivers-connected-2030.pdf
657. Hess LM, et al. (2021) BMC Health Serv Res, 21: 894.
658. Fenton A, et al. (2022) Support Care Cancer, 30: 9625.
659. Oakley-Girvan I, et al. (2023) PLOS Digit Health, 2: e0000173.
660. Ozluk P, et al. (2022) J Med Internet Res, 24: e28504.
661. Guessi Margarido M, et al. (2022) NPJ Digit Med, 5: 33.
662. Hu K, et al. (2023) JAMA Netw Open, 6: e2249560.
663. Williams CG, et al. (2022) Genome Med, 14: 68.
664. Tang F, et al. (2009) Nat Methods, 6: 377.
665. Fan L, et al. (2022) Cancer Res, 82: 2034.
666. Tian L, et al. (2022) Nat Biotechnol, 41: 773.
667. Peng Z, et al. (2022) J Transl Med, 20: 302.
668. Zhang Q, et al. (2022) Nat Commun, 13: 5983.
669. Kim H, et al. (2020) Nat Genet, 52: 891.
670. Luebeck J, et al. (2023) Nature, 616: 798.
671. Hung KL, et al. (2021) Nature, 600: 731.
672. Lange JT, et al. (2022) Nat Genet, 54: 1527.
673. Hung KL, et al. (2022) Nat Genet, 54: 1746.
674. Wu S, et al. (2019) Nature, 575: 699.
675. Zhu Y, et al. (2021) Cancer Cell, 39: 694.
676. Gu X, et al. (2020) J Exp Clin Cancer Res, 39: 215.
677. Zeng X, et al. (2020) Signal Transduct Target Ther, 5: 277.
678. ClinicalTrials.gov. Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy, in Subjects With Tumors With Oncogene Amplifications (POTENTIATE). Accessed: July 31, 2023. Available from: https://www.clinicaltrials.gov/study/NCT05827614
679. Dubash SR, et al. (2016) J Nucl Med, 57: 1207.
680. Bauer D, et al. (2023) Nat Protoc, 18: 1659.
681. Stanczak MA, et al. (2022) Sci Transl Med, 14: eabj1270.
682. ClinicalTrials.gov. Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients – Full Text View – ClinicalTrials.gov. Accessed: July 5, 2023. Available from: https://clinicaltrials.gov/ct2/show/NCT05078866
683. Shreve JT, et al. (2022) Am Soc Clin Oncol Educ Book, 42: 1.
684. Torrente M, et al. (2022) Cancers (Basel), 14.
685. Chen RJ, et al. (2022) Cancer Cell, 40: 865.
686. Han M, et al. (2023) Nature, 615: 712.
687. (2023) Nat Med, 29: 793.
688. Wang K, et al. (2018) PLoS One, 13: e0205548.
689. Grewal JK, et al. (2019) JAMA Netw Open, 2: e192597.
690. Kather JN, et al. (2019) Nat Med, 25: 1054.
691. Weiss J, et al. (2023) Nat Commun, 14: 2797.
692. Tran KA, et al. (2021) Genome Med, 13: 152.
693. Kong J, et al. (2022) Nat Commun, 13: 3703.
694. Michel A, et al. (2023) Breast Cancer Res Treat, 200: 237.
695. Kar A, et al. (2022) Biomaterials, 283: 121435.
696. Beg S, et al. (2022) Drug Discov Today, 27: 103314.
697. Mohamed MR, et al. (2023) Cancer, 129: 1096.
698. Partridge AH, et al. (2002) J Natl Cancer Inst, 94: 652.
699. Ma X, et al. (2023) Adv Sci (Weinh), 10: e2205343.
700. Du W, et al. (2023) Science Advances, 9: eadh5325.

References 701-750

701. Pew Research Center. About one-in-five Americans use a smart watch or fitness tracker. Accessed: July 5, 2023. Available from: https://www.pewresearch.org/short-reads/2020/01/09/about-one-in-five-americans-use-a-smart-watch-or-fitness-tracker/
702. Low CA (2020) NPJ Digit Med, 3: 140.
703. Teo NR, et al. (2023) Semin Oncol Nurs, 39: 151403.
704. Low CA, et al. (2018) Ann Behav Med, 52: 88.
705. Ohri N, et al. (2019) Int J Radiat Oncol Biol Phys, 105: 745.
706. Kos M, et al. (2023) Crit Rev Oncol Hematol, 185: 103979.
707. Torrente M, et al. (2022) Clin Med (Lond), 22: 36.
708. Thanarajasingam G, et al. (2023) medRxiv.
709. Shi DD, et al. (2022) Cancer Cell, 40: 939.
710. Pal S, et al. (2022) Cancer Cell, 40: 957.
711. Sonabend AM, et al. (2023) Lancet Oncol, 24: 509.
712. Enam SF, et al. (2022) Sci Adv, 8: eabq4882.
713. Yuan B, et al. (2022) Hum Vaccin Immunother, 18: 2055417.
714. Yu MW, et al. (2021) Front Immunol, 12: 676301.
715. Xiong Q, et al. (2023) Front Oncol, 13: 1192128.
716. Liau LM, et al. (2023) JAMA Oncol, 9: 112.
717. Mellenthin C, et al. (2022) Cancers (Basel), 14.
718. Owens DK, et al. (2019) JAMA, 322: 438.
719. Yang J, et al. (2021) Cancer Commun (Lond), 41: 1257.
720. ClinicalTrials.gov. A Study to Establish a New Onset Hyperglycemia and Diabetes Cohort (NOD). Accessed: July 5, 2023. Available from: https://www.clinicaltrials.gov/study/NCT03731637
721. National Cancer Institute. Pancreatic Cancer Detection Consortium (PCDC). Accessed: July 5, 2023. Available from: https://prevention.cancer.gov/major-programs/pancreatic-cancer-detection-consortium-pcdc
722. Lee MS, et al. (2023) Nature, 616: 339.
723. Nwosu ZC, et al. (2023) Nature, 618: 151.
724. Chen Y, et al. (2022) Cancer Cell, 40: 818.
725. Freed-Pastor WA, et al. (2021) Cancer Cell, 39: 1342.
726. Roth MT, et al. (2020) F1000Res, 9.
727. Kemp SB, et al. (2023) Cancer Discov, 13: 298.
728. Strickler JH, et al. (2023) N Engl J Med, 388: 33.
729. Yeo D, et al. (2022) Mol Ther Oncolytics, 24: 561.
730. Kho ZY, et al. (2018) Front Microbiol, 9: 1835.
731. Doocey CM, et al. (2022) BMC Microbiol, 22: 53.
732. Purcell RV, et al. (2017) PLoS One, 12: e0171602.
733. Vijay-Kumar M, et al. (2010) Science, 328: 228.
734. Weersma RK, et al. (2020) Gut, 69: 1510.
735. Ghaddar B, et al. (2022) Cancer Cell, 40: 1240.
736. Feng TY, et al. (2022) Cancer Immunol Res, 10: 1309.
737. Chen Y, et al. (2022) Front Immunol, 13: 935846.
738. Narunsky-Haziza L, et al. (2022) Cell, 185: 3789.
739. Dohlman AB, et al. (2022) Cell, 185: 3807.
740. Liu L, et al. (2022) JAMA Oncol, 8: 1059.
741. Si W, et al. (2022) Gut, 71: 521.
742. Eng L, et al. (2023) J Clin Oncol, 41: 3122.
743. Stein-Thoeringer CK, et al. (2023) Nat Med, 29: 906.
744. National Institutes of Health. Impact of NIH Research. Accessed: July 5, 2023. Available from: https://www.nih.gov/about-nih/what-we-do/impact-nih-research/serving-society/direct-economic-contributions
745. National Institutes of Health. Missions and Goals. Accessed: July 5, 2023. Available from: https://www.nih.gov/about-nih/what-we-do/mission-goals
746. National Institutes of Health. FY 2022 By the Numbers: Extramural Grant Investments in Research – NIH Extramural Nexus. Accessed: 2023July 5. Available from: https://www.ncbi.nlm.nih.gov/pubmed/
747. ARPA-H. New ARPA-H program to develop novel technologies for more precise cancer tumor removal. Accessed: August 2, 2023. Available from: https://arpa-h.gov/news/psi/
748. The White House. Fact Sheet: President Biden Reignites Cancer Moonshot to End Cancer as We Know It. Accessed: July 5, 2023. Available from: https://www.whitehouse.gov/briefing-room/statements-releases/2022/02/02/fact-sheet-president-biden-reignites-cancer-moonshot-to-end-cancer-as-we-know-it/
749. The ASCO Post. President Biden Prioritizes Cancer Research, Access to Care in FY 2024 Budget Proposal. Accessed: July 5, 2023. Available from: https://ascopost.com/issues/april-10-2023/president-biden-prioritizes-cancer-research-access-to-care-in-fy-2024-budget-proposal/
750. National Cancer Institute. Congressional Justification FY 2024. Accessed: July 5, 2023. Available from: https://www.cancer.gov/about-nci/budget/congressional-justification/fy2024-nci-congressional-justification.pdf

References 751-801

751. The White House. FACT SHEET: President Biden’s Budget Accelerates Progress Toward the Goal of Ending Cancer as We Know It. Accessed: July 5, 2023. Available from: https://www.whitehouse.gov/ostp/news-updates/2023/03/09/fact-sheet-cancer-fy24/
752. Hitt E (2008) Mol Oncol, 2: 290.
753. Office of the Budget NIH. Biomedical Research and Development Price Index: Fiscal Year 2022 Update and Projections for FY 2023–FY 2028. Accessed: July 5, 2023. Available from: https://officeofbudget.od.nih.gov/pdfs/FY23/gbi/BRDPI%20Proj%20Memo%20-%20February%202023%20(Final).pdf
754. National Cancer Institute. NCI Full Year Funding Policy for RPG Awards FY 2023. Accessed: July 5, 2023. Available from: https://www.ncbi.nlm.nih.gov/pubmed/
755. National Cancer Institute. MERIT Award (R37). Accessed: July 14, 2022. Available from: https://www.cancer.gov/grants-training/grants-funding/funding-opportunities/merit
756. National institutes of Health. RFA-CA-22-050: NCI Cancer Moonshot Scholars Diversity Program (CMSDP) (R01 Clinical Trial Optional). Accessed: July 5, 2023. Available from: https://www.ncbi.nlm.nih.gov/pubmed/
757. STAT News. Academia’s postdoc system is teetering, imperiling efforts to diversify life sciences. Accessed: July 5, 2023. Available from: https://www.statnews.com/2023/06/06/postdoc-system-teetering-imperiling-life-sciences-diversity/
758. National Postdoctoral Associations. 2023 Postdoctoral Barriers to Success. Accessed: July 5, 2023. Available from: https://cdn.ymaws.com/www.nationalpostdoc.org/resource/resmgr/docs/2023_postdoctoral_barriers_t.pdf
759. National Science Foundation. Restricted Data Analysis System for the Survey of Earned Doctorates. Accessed: July 5, 2023. Available from: https://ncsesdata.nsf.gov/rdas/#/
760. National institutes of Health. NOT-OD-23-084: Request for Information (RFI): Re-envisioning U.S. Postdoctoral Research Training and Career Progression within the Biomedical Research Enterprise. Accessed: July 5, 2023. Available from: https://www.ncbi.nlm.nih.gov/pubmed/
761. Bleyer A, et al. (2018) Pediatric Blood Cancer, 65: e27074.
762. Koo KC, et al. (2018) BMC Cancer, 18: 468.
763. Chow CJ, et al. (2013) J Am Coll Surg, 216: 774.
764. Unger JM, et al. (2021) J Natl Cancer Inst, 113: 244.
765. Unger JM, et al. (2019) J Natl Cancer Inst, 111: 245.
766. Faulk KE, et al. (2020) PLoS ONE, 15: e0230824.
767. Nipp RD, et al. (2019) Oncologist, 24: 1048.
768. Unger JM, et al. (2016) Am Soc Clin Oncol Educ Book, 35: 185.
769. Institute of Medicine. Barriers to patient recruitment and physician participation. Accessed: June 30, 2022. Available from: https://www.ncbi.nlm.nih.gov/pubmed/
770. U.S. Food and Drug Administration. Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials Guidance for Industry. Accessed: July 5, 2023. Available from: https://www.fda.gov/media/157635/download
771. U.S. Food and Drug Administration. Decentralized Clinical Trials for Drugs, Biological Products, and Devices. Accessed: July 5, 2023. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/decentralized-clinical-trials-drugs-biological-products-and-devices
772. Fashoyin-Aje LA, et al. (2023) Clin Cancer Res: OF1.
773. U.S. Food and Drug Administration. Accelerated Approval. Accessed: July 5, 2023. Available from: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/accelerated-approval
774. Wang S, et al. (2022) Drug Discov Today, 27: 1236.
775. U.S. Food and Drug Administration. Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics | FDA. Accessed: July 5, 2023. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-considerations-support-accelerated-approval-oncology-therapeutics
776. Merino M, et al. (2023) J Clin Oncol, 41: 2706.
777. U.S. Food and Drug Administration. Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases. Accessed: July 5, 2023. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/optimizing-dosage-human-prescription-drugs-and-biological-products-treatment-oncologic-diseases
778. The Washington Post. Cancer patients are confronting widespread shortages of chemotherapy drugs. Accessed: July 5, 2023. Available from: https://www.washingtonpost.com/health/2023/06/05/cancer-drug-shortages/
779. National Cancer Institute. Discovery – Cisplatin and The Treatment of Testicular and Other Cancers. Accessed: July 5, 2023. Available from: https://www.cancer.gov/research/progress/discovery/cisplatin
780. The New York Times. Drug Shortages Near an All-Time High, Leading to Rationing. Accessed: July 5, 2023. Available from: https://www.nytimes.com/2023/05/17/health/drug-shortages-cancer.html
781. National Cancer institute. Clinical Trials Innovation Unit. Accessed: July 5, 2023. Available from: https://www.cancer.gov/research/infrastructure/clinical-trials/ctiu
782. Pond MA, et al. (2023) Clin Transl Sci, 16: 412.
783. American Cancer Society Cancer Action Network. Congress Should Provide Higher Funding for CDC Cancer Programs and the National Breast and Cervical Cancer Early Detection Program. Accessed: July 5, 2023. Available from: https://www.fightcancer.org/sites/default/files/fy24_nbccedp_fact_sheet_final_2.28.23.pdf
784. Centers for Disease Control and Prevention. About the National Breast and Cervical Cancer Early Detection Program | CDC. Accessed: July 5, 2023. Available from: https://www.cdc.gov/cancer/nbccedp/about.htm
785. Healio. Colorectal cancer screening for ‘vulnerable’ patients higher in Medicaid expansion states. Accessed: July 5, 2023. Available from: https://www.healio.com/news/gastroenterology/20230522/colorectal-cancer-screening-for-vulnerable-patients-higher-in-medicaid-expansion-states
786. Friedman AS, et al. (2022) Am J Public Health, 112: 1630.
787. Centers for Disease Control and Prevention. How many cancers are linked with HPV each year? Accessed: July 14, 2022. Available from: https://www.cdc.gov/cancer/hpv/statistics/cases.htm
788. U.S. Food and Drug Administration. Results from the Annual National Youth Tobacco Survey | FDA. Accessed: July 5, 2023. Available from: https://www.fda.gov/tobacco-products/youth-and-tobacco/results-annual-national-youth-tobacco-survey#2022%20Findings%20on%20Youth%20Tobacco
789. Ali FRM, et al. (2023) MMWR Morb Mortal Wkly Rep, 72: 672.
790. U.S. Food and Drug Administration. Operational evaluation of certain components of FDA’s tobacco program. Accessed: July 5, 2023. Available from: https://reaganudall.org/sites/default/files/2022-12/Tobacco%20report%20210pm.pdf
791. U.S. Food and Drug Administration. FDA and NIH Award Funding for New Center for Rapid Surveillance of Tobacco. Accessed: July 5, 2023. Available from: https://www.fda.gov/tobacco-products/ctp-newsroom/fda-and-nih-award-funding-new-center-rapid-surveillance-tobacco
792. American Childhood Cancer Organization. US Childhood Cancer Statistics. Accessed: July 5, 2023. Available from: https://www.acco.org/us-childhood-cancer-statistics/
793. Congerss.gov. S.4120 – 117th Congress (2021-2022): Childhood Cancer STAR Reauthorization Act. Accessed: July 5, 2023. Available from: https://www.congress.gov/bill/117th-congress/senate-bill/4120
794. National Institutes of Health. Gabriella Miller Kids First Pediatric Research Program. Accessed: July 5, 2023. Available from: https://www.ncbi.nlm.nih.gov/pubmed/
795. Congress.gov. H.R.3391 – 118th Congress (2023-2024): Gabriella Miller Kids First Research Act 2.0. Accessed: July 5, 2023. Available from: https://www.congress.gov/bill/118th-congress/house-bill/3391
796. Georgetown University Health Policy Inititative. Millions of Children May Lose Medicaid: What Can Be Done to Help Prevent Them From Becoming Uninsured? Accessed: July 5, 2023. Available from: https://ccf.georgetown.edu/2022/02/17/millions-of-children-may-lose-medicaid-what-can-be-done-to-help-prevent-them-from-becoming-uninsured/
797. National Cancer Institute. NCI awards $50 million for new Persistent Poverty Initiative – NCI. Accessed: July 5, 2023. Available from: https://www.cancer.gov/news-events/press-releases/2023/nci-launches-persistent-poverty-initiative
798. National Cancer Institute. Statistics and Graphs | Division of Cancer Control and Population Sciences (DCCPS). Accessed: July 5, 2023. Available from: https://cancercontrol.cancer.gov/ocs/statistics
799. Jiang C, et al. (2022) Cancer, 128: 828.
800. Centers for Disease Control and Prevention. Health Effects of Cigarette Smoking. Accessed: July 5, 2023. Available from: https://www.cdc.gov/tobacco/data_statistics/fact_sheets/health_effects/effects_cig_smoking/index.htm
801. Nargis, et al. (2023) Am J Prev Med, 65: 322.